

Kaneka invests into Spanish biotech company

18 May 2018 | News

Japan based Kaneka Corporation has acquired a 34.8 per cent share of AB-Biotics, a Spanish biotech company focusing on research, development, and distribution of its own products using lactic acid bacteria.



At the same time, Kaneka has concluded a license agreement with ABB to grant Kaneka the exclusive rights for production and sales of ABB's products in North America and Japan.

Japan based Kaneka Corporation has acquired a 34.8 per cent share of AB-Biotics, a Spanish biotech company focusing on research, development, and distribution of its own products using lactic acid bacteria.

At the same time, Kaneka has concluded a license agreement with ABB to grant Kaneka the exclusive rights for production and sales of ABB's products in North America and Japan. Kaneka aims to accomplish Yen 10 billion sales in 2022 by developing and launching differentiated new products in a promising and fast-growing market, enjoying the synergy effect between ABB's and Kaneka's technology and products.

Lactic acid bacteria have been drawing people's attention for their effect and efficacy not only to intestinal function and immune system, but also to allergic symptoms and infectious diseases. The interest and business of dairy products such as yoghurt, functional foods and dietary supplements containing lactic acid bacteria is also rapidly increasing.

Kaneka has been expanding its functional food business globally such as regenerative co-enzyme Q10 (Kaneka QH), polyphenol derived from licorice (Kaneka Gravonoid) and plant-derived lactic acid bacillus, fully supported by the evidence data regarding its safety and beneficial effects to humans.